Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon

Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Philip Brainin, Maria da Conceição Vieira de Melo, Rodrigo Medeiros de Souza, Janaina Mazaro, Karine Oliveira Lima, Júnia Silva Resende, Isabelle Victória Martins Vieira, Ednilson da Silva Mesquita, Luan Oliveira Matos, Isabelle Caroline Silva Dutra, Giuseppe Palmisano, Carsten Wrenger, Claudio Romero Farias Marinho, Rita do Socorro Uchoa da Silva

1 Health and Sport Science Center, Federal University of Acre, Rio Branco, Acre, Brazil, 2 Multidisciplinary Center, Federal University of Acre, Cruzeiro do Sul, Acre, Brazil, 3 Herlev-Gentofte University Hospital, Hellerup, Denmark, 4 Laboratory of Public Health of Acre, Acre, Brazil, 5 Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil

* m.cordeirogomes@hotmail.com

Abstract

Background

Despite completion of the vaccine schedule for hepatitis B virus (HBV), children may display levels of HBV surface antibodies (anti-HBs) that are considered inadequate for sufficient protection (<10 IU/L).

Aims

Our aim was to investigate if age and gap time between HBV vaccine doses may negatively affect the levels of anti-HBs in children, and if these relationships are modified by sex.

Methods

In a high-endemic HBV region of the western Brazilian Amazon we enrolled children who had completed the HBV vaccine schedule. All children underwent analysis of anti-HBs and a clinical examination.

Results

We included 522 children (mean age 4.3 ± 0.8 years; 50% male). Median anti-HBs was 28.4 [interquartile range (IQR) 5.4 to 128.6] IU/L and 32% had anti-HBs <10 IU/L. The median gap time from last to preceding dose was 2.4 [IQR 2.1 to 3.3] months. Levels of anti-HBs decreased with higher age (-42% per year increase [95%CI -56% to -24%], p<0.001), but not with longer gap time (+23% per month increase [95%CI -16% to +62%], p = 0.249). After adjusting for relevant confounders, gap time became significant (p = 0.032) and age remained a significant predictor of anti-HBs (p<0.001).
Conclusion

One third of assessed children displayed anti-HBs <10 IU/L. Levels of anti-HBs decreased with higher age and increased with longer gap time between the last two doses.

Introduction

Infection with hepatitis B virus (HBV) is associated with significant morbidity and mortality, and constitutes a major public health challenge [1]. The virus may lead to both acute and/or chronic infection, potentially resulting in severe liver damage [1,2]. Approximately 50% of all people are considered to live in high-endemic areas where chronic HBV affects more than 8% of the population [3,4]. In Brazil, the occurrence of HBV is heterogeneously distributed [5], such that the western Brazilian Amazon has the highest endemicity in the country [6]. In addition, this region suffers from a high prevalence of hepatitis delta virus (HDV) [5,7,8], which is associated with super- and co-infections of patients already infected with HBV [8].

Brazil introduced the HBV vaccine program in 1989 for children <10 years old residing in high-endemic areas of the Amazon and in 1997 it was expanded to include all children below one year throughout the country [9]. The current Brazilian schedule for hepatitis B vaccine adopts four doses, of which the first is a monovalent hepatitis B vaccine given at birth and the others are pentavalent vaccines given at 2, 4 and 6 months. Each dose of the vaccine contains 10 μg hepatitis B surface antigen (HBsAg) according to the World Health Organization (WHO) recommendation [10–13].

Transmission of HBV may occur parenterally, sexually and vertically (mother-child) [14–16] and about 90% of perinatally infected children become chronic carriers [4]. For children aged one to five years the risk of becoming a carrier decreases to 25–30%, while an immunocompetent adult has an approximate risk of 5% when encountering the virus [17]. Therefore, completion of the vaccine program is of great importance during childhood to ensure adequate protection. However, recent studies have suggested that the protective effect of the vaccine, as defined by the level of HBV surface antibodies (anti-HBs), may be affected by age and sex [18–20]. Several studies have demonstrated that anti-HBs may decrease with higher age [21–23] and how sex potentially modifies the immune response to viral vaccines [24,25]. Specifically, a greater humoral and cell-mediated immune response has been shown in female children and adults [25].

Although the state of Acre, located in the western Brazilian Amazon, has the highest prevalence and incidence of HBV in Brazil, and accounts for 25% of the reported cases of HDV [26], there is no current study being done to investigate HBV in children in this region of the Amazon. Hence, we aimed to investigate levels of anti-HBs in children who had completed the vaccination schedule and were from this region of the Amazon. We hypothesized that age and gap time between vaccine doses may affect levels of HBV antibodies and that these relationships are modified by sex [24,27].

Material and methods

Study subjects

This was a cross-sectional study conducted in Cruzeiro do Sul (Acre, Brazil), located in the western Amazon. We included children (age two to five years) born between 2014 and 2016 who commenced on the national vaccine schedule regardless of number of completed doses.
In collaboration with local healthcare units \((n = 24)\) and kindergartens \((n = 19)\), we selected study participants to be invited at random. Study sites were distributed between urban \((n = 31)\) and rural \((n = 12)\) areas. The distribution of participants enrolled in this study corresponded to the proportion of children associated with each healthcare unit/kindergarten in the city. Prior to study enrollment, parents and/or legal guardians were informed about the study, procedure and outcome. Because of limited access to healthcare units and lack of cellular network in rural areas, study participants in these areas \((n = 146\) children\) were not randomly invited. Instead, healthcare professionals from each rural unit were responsible for inviting study participants. From July to December 2019, a total of 542 children were included in the study (Fig 1). Nineteen children were excluded due to lack of proof for vaccination, thus yielding a total study population of 522 participants.

### Study data

Children had height and weight measured and the body mass index (BMI) was calculated and classified according to age and sex specific guidelines defined by the WHO [28]. Information on vaccine status came from vaccine proofs and questionnaires.

### Analysis of HBV markers

All blood samples underwent centrifugation \((2127 \times g, 10\) minutes\) and were initially stored at -20°C at Federal University of Acre, Campus Floresta. Serological tests were performed at the Central Laboratory of Public Health of Acre. We conducted immunological analyses by commercial Chemiluminescent Microparticle Immunoassays (Architect System, Abbott)

---

**Fig 1. Study design flowchart.** Consort diagram showing the inclusion of children in this study.

https://doi.org/10.1371/journal.pone.0253752.g001
Diagnostics, Sligo, Ireland or Wiesbaden, Germany) which were performed according to the manufacturer’s instructions. Three serological markers were analyzed: Anti-HBs [ARCHITECT Anti-HBs, limit of detection 0–1000 IU/L, specificity 99.67% [95%CI 99.22 to 99.89], sensitivity 97.54% [95%CI 95.97 to 98.62], HBsAg [ARCHITECT HBsAg Qualitative, specificity 100% [95%CI 99.41 to 100], sensitivity 99.80% [95%CI 98.90 to 99.99%] and antibody to hepatitis B core antigen (anti-HBc) [ARCHITECT Anti-HBc II, specificity 100% [95%CI 98.42 to 100], sensitivity 100% [95%CI 99.10 to 100%]. The first marker, anti-HBs, was assessed quantitatively and the latter markers qualitatively.

Statistics
Continuous normally distributed variables were reported as mean values ± standard deviations and median [interquartile range (IQR)] was used for non-Gaussian distributed variables. Absolute and relative frequencies were described for categorical variables. Anti-HBs <10 IU/L, 10–99 IU/L and >100 IU/L and age <3, 3, 4 and ≥ 5 years old were used as defined categories. Characteristics of the participants stratified according to categories of anti-HBs were compared using Cuzick’s non-parametric test for trend and linear regression models. Pearson’s χ2 test was used for categorical variables, except when we had cells frequencies ≤5. In these cases, Fisher’s exact test was applied. Spearman’s test was used to examine the relationship between categories of anti-HBs and age.

We assessed the relationship between anti-HBs and age as well as anti-HBs and gap time between last and preceding vaccine dose. These relationships were assessed using linear regression models. We estimated the relative change in anti-HBs with 95% confidence interval (CI). In the same models we adjusted for (i) sex, (ii) mother’s HBsAg carrier status, (iii) number of total vaccine doses and (iv) living area (rural vs urban). A potential interaction with sex was examined in linear regression models. We considered two-sided p-values <0.050 as statistically significant. All statistical analyses were performed using Stata version 14.1 (StataCorp LP, College Station, TX).

Ethics
The parents and/or legal guardians of all included study participants provided written informed consent according to the 2nd Declaration of Helsinki. This study was approved by the Research Ethics Committee of the Acre State Hospital Foundation (CAAE: 09413619.8.0000.5009).

Results
Baseline data
The study population included a total of 522 (50% males) children with a mean age of 4.3 ± 0.8 years (range 2.6 to 5.9 years), who were examined in 43 healthcare units and kindergartens in Cruzeiro do Sul, Acre, Brazil. The median level of anti-HBs was 28.4 [IQR 5.4 to 128.6] IU/L and 32% (n = 165) displayed levels of anti-HBs below 10 IU/L (Fig 2). All included children were negative to serology for HBsAg and anti-HBc. A total of 98% of the study population received ≥3 vaccines and median time from first to last vaccine dose was 7.3 [IQR 6.5 to 9.3] months.

When the population was stratified according to pre-defined categories of anti-HBs, age and time interval from last vaccination to examination date varied significantly across these categories (p trend<0.001; Table 1). No statistical difference was observed in sex, BMI, potential risk factors for HBV (sharing toothbrush, dental treatment, surgery, hospitalization) or
parameters of socioeconomic status. When the population was stratified according to sex, only BMI differed significantly between males and females (S1 Table).

Antibody titers and age

Children with age equal to or greater than five years old, 40% (n = 51) had anti-HBs <10 IU/L. Age categories differed significantly across categories of anti-HBs (Spearman’s rho = -0.20, p < 0.001; Fig 2). When assessing anti-HBs as a continuous variable, anti-HBs decreased by 42% per year increase in age ([95%CI -56% to -24%], p < 0.001; Fig 3A; Table 2). In multivariable analyses, the association with anti-HBs remained significant (43% decrease per year increase in age [95%CI -57% to -25%], p < 0.001). This relationship between anti-HBs and age was not modified by sex (p = 0.425). In both, unadjusted and adjusted models anti-HBs data was log-transformed to have a normal distribution. The influence of age in antibodies was also found in a logistic regression model to assess risk of anti-HBs <10 UI/L (Odds ratio 0.63 [95% CI 0.50 to 0.80] p < 0.001, Fig 4).

Antibody titers and gap time

Median gap time between last and preceding vaccine dose was 2.4 [IQR 2.1 to 3.3] months. After log-transformation in anti-HBs and gap time, because their non-normal distribution, linear regression models were tested. No association between gap time and anti-HBs was found in unadjusted (+23%, 95% CI, -16% to +62%, p = 0.249), but it was detected in adjusted models (+45%, 95% CI, +4% to +87%, p = 0.032; Table 2; Fig 3B). Sex did not modify the relationship between anti-HBs and gap time of the last two doses (p = 0.949). The risk of anti-HBs <10 UI/L was influenced by this interval of doses (Odds ratio 1.50 [95% CI 1.05 to 2.13] p 0.024, Fig 4).
Table 1. Baseline information about children, their hepatitis B vaccine schedule and potential factors of risk to exposure to HBV, stratified by anti-HBs titer.

| Categories of anti-HBs | Total | <10IU/L | 10-99IU/L | ≥100IU/L | p trend |
|------------------------|-------|---------|-----------|----------|---------|
| N (%)                  | 522 (100%) | 165 (31.6%) | 200 (38.3%) | 157 (30.1%) |         |
| **Baseline**           |        |         |           |          |         |
| Mean age, years        | 4.3 ±0.8 | 4.5 ±0.8 | 4.3 ±0.9 | 4.1 ±0.8 | <0.001  |
| Male, n(%)             | 259 (49.6%) | 78 (47.3%) | 99 (49.5%) | 82 (52.2%) | 0.670   |
| BMI in percentiles*, n(%) |        |         |           |          | 0.084   |
| <25%                   | 115 (22.0%) | 25 (15.2%) | 50 (25.3%) | 40 (25.5%) |         |
| 25–75%                 | 227 (43.5%) | 81 (49.4%) | 86 (43.4%) | 60 (38.2%) |         |
| >75%                   | 177 (34.5%) | 58 (35.4%) | 62 (31.3%) | 57 (36.3%) |         |
| Urban area, n(%)       | 376 (72.0%) | 120 (72.7%) | 142 (71.0%) | 114 (72.6%) | 0.920   |
| **Mother’s education*, n(%)** |        |         |           |          | 0.385   |
| No education           | 9 (1.7%) | 2 (1.2%) | 6 (3.0%) | 1 (0.6%) |         |
| 1–4 years              | 41 (7.9%) | 12 (7.3%) | 18 (9.0%) | 11 (7.0%) |         |
| 5–8 years              | 102 (19.5%) | 26 (15.8%) | 41 (20.5%) | 35 (22.3%) |         |
| >8 years               | 369 (70.7%) | 125 (75.8%) | 135 (67.5%) | 109 (69.4%) |         |
| **Father’s education*, years** |        |         |           |          | 0.200   |
| No education           | 34 (6.5%) | 7 (4.2%) | 20 (10.0%) | 7 (4.5%) |         |
| 1–4 years              | 54 (10.3%) | 20 (12.1%) | 16 (8.0%) | 18 (11.5%) |         |
| 5–8 years              | 102 (19.5%) | 31 (18.8%) | 39 (19.5%) | 32 (20.4%) |         |
| >8 years               | 292 (55.9%) | 97 (58.8%) | 105 (52.5%) | 90 (57.3%) |         |
| **Family income*, BRL** |        |         |           |          | 0.638   |
| <1,000                 | 243 (46.6%) | 78 (47.3%) | 92 (46.0%) | 73 (46.5%) |         |
| 1,000–2,999            | 227 (43.5%) | 73 (44.2%) | 86 (43.0%) | 68 (43.3%) |         |
| 3,000–4,999            | 20 (3.8%) | 5 (3.0%) | 10 (5.0%) | 5 (3.2%) |         |
| >5,000                 | 15 (2.9%) | 7 (4.2%) | 4 (2.0%) | 4 (2.5%) |         |
| **Vaccine**            |        |         |           |          | 0.608   |
| Number of vaccine doses |        |         |           |          |         |
| 1                      | 3 (0.6%) | 1 (0.6%) | 2 (1.0%) | 0 (0.0%) |         |
| 2                      | 9 (1.7%) | 3 (1.8%) | 5 (2.5%) | 1 (0.6%) |         |
| 3                      | 41 (7.9%) | 16 (9.7%) | 15 (7.5%) | 10 (6.4%) |         |
| 4                      | 469 (89.8%) | 145 (87.9%) | 178 (89.0%) | 146 (93.0%) |         |
| **Gap time, months**   |        |         |           |          |         |
| First to last dose     | 7.3 (6.5, 9.3) | 7.1 (6.5, 8.6) | 7.4 (6.5, 9.5) | 7.4 (6.6, 9.6) | 0.126   |
| Last to preceding dose | 2.4 (2.1, 3.3) | 2.3 (2.0, 3.0) | 2.5 (2.1, 3.6) | 2.5 (2.1, 3.5) | 0.114   |
| Last dose to blood collection | 43.7 (35.9, 51.7) | 46.4 (38.3, 54.8) | 44.0 (35.9, 51.9) | 40.6 (32.9, 48.6) | <0.001  |
| **Exposure**           |        |         |           |          |         |
| Degree of family with HBV*, n(%) |        |         |           |          | 0.827   |
| • 1<sup>st</sup>       | 23 (4.4%) | 8 (4.8%) | 9 (4.5%) | 6 (3.8%) |         |
| • 2<sup>nd</sup>       | 36 (6.9%) | 13 (7.9%) | 16 (8.0%) | 7 (4.5%) |         |
| • 3<sup>rd</sup>       | 45 (8.6%) | 12 (7.3%) | 17 (8.5%) | 16 (10.2%) |         |
| • 4<sup>th</sup>       | 12 (2.3%) | 5 (3.0%) | 4 (2.0%) | 3 (1.9%) |         |
| N/A                    | 402 (77.0%) | 127 (77.0%) | 151 (75.5%) | 124 (79.0%) |         |
| HBsAg positive mother, n(%) |        |         |           |          | 0.543   |
| Yes                    | 12 (2.3%) | 4 (2.4%) | 3 (1.5%) | 5 (3.2%) |         |
| No                     | 510 (97.7%) | 161 (97.6%) | 197 (98.5%) | 152 (96.8%) |         |
| Toothbrush shared, n(%) |        |         |           |          | 0.431   |
| Yes                    | 16 (3.1%) | 7 (4.2%) | 4 (2.0%) | 5 (3.2%) |         |
| No                     | 506 (96.9%) | 122 (73.9%) | 166 (83.0%) | 129 (82.2%) |         |

(Continued)
Discussion

In the present study, we examined 522 children from Cruzeiro do Sul, Acre, Brazil, who had completed the HBV vaccine schedule. The key findings are that 32% of all children displayed anti-HBs <10 IU/L and that the levels of anti-HBs decreased with higher age. Our findings are important because the study was conducted in a HBV endemic area of the Amazon basin, where adequate protection against HBV is of utmost importance [26].

An antibody concentration equal to or greater than 10 IU/L after completing the vaccination schedule is considered protective against HBV infection [29]. A recent meta-analysis by Mahmood et al. showed that two years after completion of the vaccination program in childhood, more than 95% of individuals had anti-HBs level ≥ 10 IU/L and this rate decreased to 70% eight years later [21]. By contrast, we examined children a mean time of 3.6 years after completion of the vaccine schedule and found that only two thirds of the study population achieved titers higher than 10 IU/L. Studies have already shown that children remain protected in childhood following completion of the vaccine schedule [20,22,23,30]. This is supported by our findings, where all children had negative HBsAg or anti-HBc profiles. However, it remains

BMI: Body mass index, BRL: Brazilian reais, HBV: Hepatitis B virus, N/A: Not applicable.
Non-normally distributed variables are presented as median [interquartile range].

https://doi.org/10.1371/journal.pone.0253752.t001

Fig 3. Association between Hepatitis B antibodies and (A) age, (B) gap time. (A) Linear regression model assessing anti-HBs (log-transformed) and age. Black line indicates association correlate, and gray lines indicate 95% CI. (B) Linear regression model assessing both log-transformed anti-HBs and gap time (months) between last and preceding vaccine dose. Black line indicates association correlate, and gray lines indicate 95% CI.

https://doi.org/10.1371/journal.pone.0253752.g003
unclear whether the protection continues into adulthood despite decreasing antibodies [23,31].

While some studies have shown persistent protection up to 20 years after completion of the vaccine schedule [32–34], other studies have reported an increasing prevalence of HBV infection with higher age [35–38]. Specifically, one study found that in a population with high coverage of the vaccine schedule in childhood, the prevalence of HBV increased from 2.3% at age of 16 years to 8.4% at age 25 years old [37]. We found that levels of antibodies decreased with higher age, indicating that age potentially may influence the protective effect of the vaccine into adulthood.

As of today, the WHO does not support the need for a booster dose of HBV vaccine after completion of the primary vaccination schedule in immunization programmes [13]. Importantly, the response to a booster dose has been shown to decrease by age [18,23,39]. A rapid increase in anti-HBs after a challenge dose represents an anamnestic response, which is considered to indicate presence of immune memory generated after primary vaccination [39–41]. Meanwhile, it is still not elucidated whether an anamnestic response accurately reflects the immune memory [39]. The disappearance of an anamnestic effect with higher age has also been widely reported [19,33,42,43]. These findings explain why a booster dose may be of greater value if given during childhood or adolescence as compared to during adulthood.

Similarly, it has been demonstrated that low levels of anti-HBs may not ensure protection against all genotypes of the virus [44]. This is supported by in vitro studies, which have shown that low levels of vaccine-acquired anti-HBs were insufficient for neutralizing different genotypes of HBV [45,46]. In one study, polyclonal anti-HBs generated by immunization with the HBsAg genotype A vaccine inhibited only 60% of examined samples with HBsAg genotype C at titers of 30 IU/L [46]. In the present study, the median level of antibodies was 28.3 IU/L. These results are in line with another study by Stramer et al. which was carried out in blood donors in the United States [44]. The study detected six people who were HBV seronegative, but remained positive in the detection of virus DNA, despite they had been vaccinated with

| Table 2. Association between level of anti-HBs, age and gap time. |
|-----------------|-----------------|-----------------|-----------------|
| Age, per 1 year increase | Coefficient (CI 95%) | p value | Coefficient (CI 95%) | p value |
| Age, per 1 year increase | -42% (-56% to -24%) | <0.001 | -43% (-57% to -25%) | <0.001 |
| Gap time(month), per 1% increase | +23% (-16% to +62%) | 0.249 | +45% (+4% to +87%) | 0.032 |

*Adjusted model included: Gap time between last and preceding vaccine dose, sex, mothers HBsAg carrier status, number of vaccine doses and living area.
†Adjusted model included: Age, sex, mothers HBsAg carrier status, number of vaccine doses and living area.

https://doi.org/10.1371/journal.pone.0253752.t002

Fig 4. Risk of anti-HBs<10IU/L by factors associated with low anti-HB levels in a logistic regression model.

https://doi.org/10.1371/journal.pone.0253752.g004
genotype A2 vaccine. Five of them had low or undetectable titers of anti-HBs. Only one person had been infected with the genotype from which the vaccine was derived (anti-HBs 3 IU/L) [44]. This suggests that anti-HBs in low concentrations may protect against infection by genotype A2, but that higher titers are required to ensure protection against other genotypes of the virus. In the high-endemic state of Acre, located in the Amazon basin, at least three genotypes of the hepatitis B virus have already been described [47].

The purpose of the HBV vaccine schedule is to provide adequate protection against HBV infection throughout child- and adulthood. Considering that we found overall low levels of anti-HBs, and that anti-HBs decreased significantly with age, in a high-endemic HBV and HDV area of the Amazon, this calls for novel attention on this topic.

However, children with a longer interval between the last two doses had higher levels of anti-HBs in this study. Due to this uncertainty of long-term protection after childhood vaccination, especially for a population that will have a higher risk of exposure during life, an extra dose would later be reasonable. In some European countries this is already done, the last dose is administrated being between 11 and 15 months of life, after a birth dose for high-risk infants and doses at 2, 3 and 4 months [23].

Although we had no long-term follow-up on HBV infection rate in the assessed population, further studies are encouraged to establish if the duration of protection generated by this vaccine extends into adulthood.

Strengths and limitations

Study participants enrolled in rural areas were not randomized because of limited access to healthcare units and lack of cellular network. This could represent a potential source of bias in our study design. Although our multivariable models were adjusted for living area (urban vs rural), some children were vaccinated in both urban and rural areas. All questionnaires used to extract information from study participants involved self-reported information.

Some of the study participants received at least one vaccine dose delayed and twelve participants did not complete the schedule. As well, some study participants received 3 doses while others received 4 doses. This could potentially impact the levels of anti-HBs we measured. However, our multivariable models included this information.

Carrier status for HBsAg of the mothers were not tested in this study but was instead self-reported. A meta-analysis showed that the proportion of individuals with anti-HBs ≥10IU/L was more than twice as high for children with HBV positive mothers [14]. A close contact to the carrier mother during infancy is believed to work as a natural booster [14].

Conclusion

In a high-endemic HBV area in the western Amazon, 32% of children who completed the HBV vaccine schedule had anti-HBs <10 IU/L. A vaccine schedule for HBV with an extra dose in later years of childhood, might be considerate as a strategy to ensure protective anti-HBs levels in endemic area. Future studies should address whether levels of anti-HBs <10IU/L, measured during childhood, provide adequate protection against HBV into adulthood.

Supporting information

S1 Table. Baseline information stratified by sex. BMI: Body mass index, BRL: Brazilian reais, HBV: Hepatitis B virus, N/A: Not applicable. Non-normally distributed variables are presented as median [interquartile range]. " Variable with missing or not informed data.

(PDF)
S1 File.
(XLS)

Acknowledgments
The authors would like to thank the cooperation of the parents/legal guardians and individuals who participated in this study.

Author Contributions
Conceptualization: Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Rita do Socorro Uchoa da Silva.

Data curation: Laura Cordeiro Gomes, Rita do Socorro Uchoa da Silva.

Formal analysis: Laura Cordeiro Gomes, Philip Brainin.

Funding acquisition: Rodrigo Medeiros de Souza, Giuseppe Palmisano, Carsten Wrenger, Claudio Romero Farias Marinho.

Investigation: Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Maria da Conceicao Vieira de Melo, Janaina Mazaro, Karine Oliveira Lima, Junia Silva Resende, Isabelle Victoria Martins Vieira, Edinilson da Silva Mesquita, Luan Oliveira Matos, Isabelle Caroline Silva Dutra.

Methodology: Laura Cordeiro Gomes, Rodrigo Medeiros de Souza, Rita do Socorro Uchoa da Silva.

Project administration: Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Rita do Socorro Uchoa da Silva.

Resources: Laura Cordeiro Gomes, Rodrigo Medeiros de Souza, Giuseppe Palmisano, Carsten Wrenger, Claudio Romero Farias Marinho.

Supervision: Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Rita do Socorro Uchoa da Silva.

Validation: Laura Cordeiro Gomes, Rita do Socorro Uchoa da Silva.

Visualization: Laura Cordeiro Gomes, Philip Brainin.

Writing – original draft: Laura Cordeiro Gomes, Philip Brainin.

Writing – review & editing: Laura Cordeiro Gomes, Marina Cordeiro Gomes Sanson, Philip Brainin, Rodrigo Medeiros de Souza, Giuseppe Palmisano, Carsten Wrenger, Claudio Romero Farias Marinho, Rita do Socorro Uchoa da Silva.

References
1. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015; 5: 1–12. https://doi.org/10.1101/cshperspect.a021410 PMID: 25934461
2. Suhail M, Abdel-Hafiz H, Ali A, Fatima K, Damanhouri GA, Azhar E, et al. Potential mechanisms of hepatitis B virus induced liver injury. World J Gastroenterol. 2014; 20: 12462–12472. https://doi.org/10.3748/wjg.v20.i35.12462 PMID: 25253946
3. Te HS, Jensen DM. Epidemiology of Hepatitis B and C Viruses: A Global Overview. Clin Liver Dis. 2010; 14: 1–21. https://doi.org/10.1016/j.cld.2009.11.009 PMID: 20123436
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30: 2212–2219. https://doi.org/10.1016/j.vaccine.2011.12.116 PMID: 22273662
5. Souto FJD. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century. Rev Soc Bras Med Trop. 2016; 49: 11–23. https://doi.org/10.1590/S0037-8682-0176-2015 PMID: 26689276

6. Rueda BZG, Gonçalves LL, Rueda-Dantas MA, Ferreira BVC, Zago-Gomes M da P. Change in the Epidemiological Profile of Hepatitis B in Brazil. SN Compr Clin Med. 2019; 1: 1015–1018. https://doi.org/10.3851/LMP2595-PMID: 23792375

7. Alvarado-Mora M V., Rebello Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther. 2013; 18: 429–433. https://doi.org/10.3851/IMP2595 PMID: 23792375

8. Viana S, Paraná R, Moreira RC, Compri AP, Macedo V. High prevalence of Hepatitis B virus and Hepatitis D virus in the western Brazilian Amazon. Am Soc Trop Med Hyg. 2005; 73: 808–814. https://doi.org/10.4269/ajtmh.2005.73.808 PMID: 16222030

9. Brazil. Ministry of Health. National Health Foundation. National Immunization Program: NIP 20 years. 2nd ed. Brasilia—DF: Ministry of Health; 1998. Available: https://bvms.saude.gov.br/bvs/publicacoes/cd03_10.pdf.

10. The Secretariat of Health of Sao Paulo. Division of Immunization. Division of Hepatitis. Epidemiological Surveillance Center “Prof. Alexandre Vranjac”. Disease Coordination. Hepatitis B vaccine. Rev Saúde Pública. 2006; 40: 1137–1140. PMID: 17173175

11. Brazil. Ministry of Health. Secretariat of Health Surveillance. Department of Surveillance of Communicable Diseases. Manual of rules and procedures for vaccination. 1st ed. Brasilia—DF: Ministry of Health; 2014. Available: https://bvms.saude.gov.br/bvs/publicacoes/manual_procedimentos_vacinalao.pdf.

12. Brazil. Ministry of Health. Secretariat of Health Surveillance. Department of Epidemiological Surveillance. Technical report on the introduction of the pentavalent vaccine: Diphtheria, tetanus, pertussis, hepatitis B (recombinant) and Haemophilus influenzae type b (conjugated) vaccine. Brasilia; 2012. Available: http://www.sgc.goias.gov.br/upload/arquivos/2012-06/informe-tecnico-vacina-pentavalente.pdf.

13. WHO. Weekly epidemiological record. Geneva; 2017.

14. Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 2015; 62: S76–S86. https://doi.org/10.1016/j.jhep.2015.01.018 PMID: 25920093

15. Lobato C, Tavares-Neto J, Rios-Leite M, Trepo C, Viltvitski L, Parvaz P, et al. Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: Epidemiologic and biomolecular study. J Gastroenterol Hepatol. 2006; 21: 863–868. https://doi.org/10.1111/j.1440-1746.2006.04298.x PMID: 16704537

16. Burns GS, Thompson AJ. Viral hepatitis B: Clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014; 4. https://doi.org/10.1101/cshperspect.a024935 PMID: 25359547

17. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The Influence of Age on the Development of the Hepatitis B Carrier State. Proc R Soc. 1993; 253: 197–201. https://doi.org/10.1098/rspb.1993.0102 PMID: 8397416

18. Schönberger K, Riedel C, Rückinger S, Mansmann U, Jilg W, Kries R V. Determinants of long-term protection after hepatitis b vaccination in infancy: A meta-analysis. Pediatr Infect Dis J. 2013; 32: 307–313. https://doi.org/10.1097/INF.0b013e31827bd1b0 PMID: 23249904

19. van der Sande MAB, Waight P, Mendy M, Hutt P, Fulford T, Doherty C, et al. Long-Term Protection against Carriage of Hepatitis B Virus after Infant Vaccination. J Infect Dis. 2006; 193: 1528–1535. https://doi.org/10.1086/503433 PMID: 16652281

20. Lin DB, Wang H, Lee Y, Ling U. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine. 1998; 16: 1683–1687. https://doi.org/10.1016/s0264-410x(98)00050-4 PMID: 9713947

21. Mahmood S, Shah KU, Khan TM. Immune Persistence After Infant Hepatitis-B Vaccination: A Systematic Review and Meta-Analysis. Sci Rep. 2018; 8: 1–8. https://doi.org/10.1038/s41598-017-17765-5 PMID: 29316191

22. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody Levels and Protection after Hepatitis B Vaccination: Results. Ann Intern Med. 2005; 142: 333–341. https://doi.org/10.7326/0003-4819-142-5-200503010-00008 PMID: 15738452

23. Pinto M, Dawar M, Krajdien M, Naus M, Scheifele DW. Will Infant Hepatitis B Vaccination Protect into Adulthood?: Extended Canadian Experience after a 2-, 4- and 6-Month Immunization Schedule. Pediatr Infect Dis J. 2017; 36: 609–615. https://doi.org/10.1097/INF.0000000000001543 PMID: 28134742

24. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010; 10: 338–349. https://doi.org/10.1016/s1473-3099(10)70049-9 PMID: 20417416
25. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and therapeutic treatments for viral diseases. Bioessays. 2014; 34: 1050–1059. https://doi.org/10.1002/bies.201200099 PMID: 23012250

26. Brazil. Ministry of Health. Secretariat of Health Surveillance. Epidemiological Bulletin—Viral Hepatitis. Brasilia—DF; 2019. Available: http://www.aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hepatites-virais-2019.

27. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016; 6: 1–12. https://doi.org/10.1038/s41598-016-0001-8 PMID: 28442746

28. WHO. The WHO Child Growth Standards. In: The WHO Child Growth Standards [Internet]. 2020 [cited 24 Aug 2020]. Available: https://www.who.int/childgrowth/en/.

29. Zhang X, Wang J, Chen X, Yu M, Yu S, Sun Y, et al. Short-term immunogenicity of standard and accelerated hepatitis B virus vaccination schedules in healthy adults: A comparative field study in China. Biosci Rep. 2018; 38: 1–9. https://doi.org/10.1042/BSR20180846 PMID: 30201691

30. Petro TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC Infect Dis. 2014; 14: 1–8. https://doi.org/10.1186/1471-2334-14-1 PMID: 24380631

31. Lao TT. Immune persistence after hepatitis B vaccination in infancy—Fact or fancy? Hum Vaccines Immunother. 2016; 12: 1172–1176. https://doi.org/10.1080/21645515.2015.1130195 PMID: 26810256

32. Poovorawan Y, Chongsirisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand. Hum Vaccines Immunother. 2013; 9: 1679–1684. https://doi.org/10.4161/hv.24844 PMID: 23732904

33. Gabbuti A, Romanò L, Blanc P, Meacci F, Amendola A, Mele A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007; 25: 3129–3132. https://doi.org/10.1016/j.vaccine.2007.01.045 PMID: 17291637

34. AlFaleh F, AlShehri S, AlAnsari S, AlJeffri M, AlMazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008; 57: 404–409. https://doi.org/10.1016/j.jinf.2008.08.008 PMID: 18829116

35. Jeong SH, Yim H, Yoon SH, Jee YM, Bae SH, Lee W. Changes in the intrafamilial transmission of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China. Bull World Health Organ. 2010; 138: 1090–1095. https://doi.org/10.1017/S0950268809991324 PMID: 19951454

36. Khan F, Shams S, Qureshi ID, Israr M, Khan H. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J. 2011; 8: 225. https://doi.org/10.1186/1743-422X-8-225 PMID: 21569532

37. Lao TT, Sahota DS, Law L, Cheng KY, Leung T. Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China. Bull World Heal Organ. 2014; 92: 782–789. https://doi.org/10.2471/BLT.13.133413 PMID: 25378739

38. Suen SSH, Lao TT, Chan OK, Lau TK, Leung TY, Chan PKS. Relationship between age and prevalence of hepatitis B infection in first-year university students in Hong Kong. Infection. 2013; 41: 529–535. https://doi.org/10.1007/s15010-012-0379-6 PMID: 23233215

39. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnet W, Mcmahon BJ, et al. Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and. Pediatrics. 2015; 120: e373–e381. https://doi.org/10.1542/peds.2007-0131 PMID: 17636112

40. FitzSimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005; 23: 4158–4166. https://doi.org/10.1016/j.vaccine.2005.03.017 PMID: 15964484

41. Banatvala J, Dämme P Van, Oehsen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2001; 19: 877–885. https://doi.org/10.1016/S0264-410X(00)00224-3

42. Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010; 38: 395–400. https://doi.org/10.1007/s15010-010-0039-7 PMID: 20589522

43. Lu C, Chiang B, Chi W, Chang M, Ni Y, Hsu H, et al. Waning Immunity to Plasma-Derived Hepatitis B Vaccine and the Need for Boosters 15 Years After Neonatal Vaccination. Hepatology. 2000; 40: 1415–1420. https://doi.org/10.1002/hep.20490 PMID: 15565627
44. Stramer SL, Ph D, Wend U, Candotti D, Ph D, Foster GA, et al. Nucleic Acid Testing to Detect HBV Infection in Blood Donors. N Engl J Med. 2011; 364: 236–247. https://doi.org/10.1056/NEJMoa1007644 PMID: 21247314

45. Hamada-Tsutsumi S, Iio E, Watanabe T, Murakami S, Isogawa M, Iijima S, et al. Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. PLoS One. 2015; 10: 1–13. https://doi.org/10.1371/journal.pone.0118062 PMID: 25693196

46. Kato M, Hamada-Tsutsumi S, Okuse C, Sakai A, Matsumoto N, Sato M, et al. Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes. J Gastroenterol. 2017; 52: 1051–1063. https://doi.org/10.1007/s00535-017-1316-3 PMID: 28197802

47. Lampe E, Mello FCA, do Espírito-Santo MP, Oliveira CMC, Bertolini DA, Gonçales NSL, et al. Nationwide overview of the distribution of hepatitis B virus genotypes in Brazil: A 1000-sample multicentre study. J Gen Virol. 2017; 98: 1389–1398. https://doi.org/10.1099/jgv.0.000799 PMID: 28631602